China’s biotech industry sees global expansion as unstoppable, despite US pressure
Chinese biotech firms are leaning harder on overseas licensing deals as US barriers rise. Industry figures say global commercialization is already irreversible.
Intelligence analysis by GPT-5.4 Mini
The article says Chinese biotech companies are pushing into overseas markets even as Washington adds investment and security restrictions. Executives argue that Europe and other markets are becoming more open to Chinese drugs and devices because of cost advantages and tight budgets.
Chinese drug makers are trying to sell and share their medicines in other countries, like a company opening stores in many cities instead of just one. Even if one big country puts up roadblocks, they are finding other places that want cheaper, useful products.
Analysis
Chinese biotech companies are continuing to expand abroad even as the US tightens restrictions and uses national security tools to slow Chinese firms' access to its market. At the Hong Kong Exchanges and Clearing Future Tech Summit in Shenzhen, Citic Securities executive Zhang Jun said the barriers in the US are real, but argued that the move by Chinese biotech firms to commercialize globally is already irreversible.
The article says overseas markets are the most profitable part of the pharmaceutical value chain, with the US still the most lucrative drug market. Even so, Chinese companies are finding traction elsewhere. According to Citic Securities, they now account for about half of global biotechnology business development deals, including out-licensing agreements.
Zhang suggested that Europe is becoming more receptive because of fiscal pressure on governments and the appeal of lower-cost Chinese innovative drugs and medical devices. That framing matters because it points to a strategy built less on direct market entry in the US and more on licensing and cross-border partnerships.
Ren Feng, co-CEO and chief scientific officer of Insilico Medicine, added that international expansion is essential for Chinese biotech firms. He said companies that only focus on the China market will struggle to build a large future, and that the weakness is often the lack of large overseas clinical teams. In his view, the practical path forward is business development deals.
The article also notes that Beijing sees biotechnology as a strategic industry tied to economic growth. That makes the sector not just a business story, but part of a larger industrial policy push.
Key points
- Chinese biotech companies are expanding abroad despite rising US restrictions and national security scrutiny.
- Citic Securities says Chinese firms account for about half of global biotechnology business development deals, including out-licensing.
- Executives say Europe may be more open to Chinese drugs and devices because of budget pressure and cost advantages.
- Insilico Medicine's leadership says international expansion is necessary for Chinese biotech firms to grow large.
- A major weakness for many Chinese firms is the lack of large overseas clinical teams, making business development deals the main path forward.
If the trend continues, Chinese biotech firms could keep winning overseas licensing and partnership deals, giving them access to global markets without needing to build everything from scratch. That could help them scale faster and bring more Chinese-developed drugs and devices to patients abroad.
The biggest risk is that US pressure spreads or intensifies, making it harder for Chinese firms to enter key markets or attract partners. The article also notes a lack of large overseas clinical teams, which could slow expansion even when foreign demand exists.
